OCT retinal scans show the eye-kidney connection

News
Article
Ophthalmology Times EuropeOphthalmology Times Europe January/February 2024
Volume 20
Issue 1

The kidney and eye are structurally similar and the diseases of the organs may present via common pathways

An illustration of human kidneys, viewed as a cross-section. Image credit: ©Crystal light – stock.adobe.com

UK researchers concluded that retinal OCT images can non-invasively be a monitor and prognostic biomarker of kidney injury. Image credit: ©Crystal light – stock.adobe.com

UK investigators, led by Tariq E. Farrah, BM, BSc, reported a link between the findings in the eye on optical coherence tomography (OCT) scans and renal pathology.1 He is from Edinburgh Kidney, British Heart Foundation/University of Edinburgh Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, and the Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.

The research team pointed out the need for novel biomarkers that track kidney injury, demonstrate a treatment response and predict outcomes in patients with chronic kidney disease (CKD). The kidney and eye are structurally and functionally similar,2,3 and the diseases of the organs may present similarly and via common pathways. They offered evidence that Bruch membrane and the glomerular basement membrane both have a network of α3, α4 and α5 type IV collagen chains.4,5 Type IV collagen inherited disease manifests with both nephropathy and retinopathy, as in Alport syndrome.6

Investigators assessed the potential of retinal OCT imaging to reliably track kidney injury, monitor treatment responses and predict outcomes in a series of prospective studies of patients with CKD who did not yet require dialysis. These 204 participants included those who underwent a kidney transplantation, those who had kidney failure and were undergoing kidney transplantation, living kidney donors, and 86 healthy volunteers.

The investigators reported that compared with healthy volunteers, “We observed similar retinal thinning and reduced macular volume in patients with CKD and in those with a kidney transplant. However, the choroidal thinning observed in CKD was not seen in patients with a kidney transplant, whose choroids resemble those of healthy volunteers.

In CKD, the degree of choroidal thinning is related to the falling estimated glomerular filtration rate (eGFR) and extent of kidney scarring. Following kidney transplantation, choroidal thickness increases rapidly (~10%) and is maintained over 1 year, whereas gradual choroidal thinning is seen during the 12 months following kidney donation. In patients with CKD, the retinal and choroidal thicknesses are independently associated with eGFR decline over 2 years.”

The researchers concluded that retinal OCT images can non-invasively be a monitor and prognostic biomarker of kidney injury.

References

1. Farrah TE, Pugh D, Chapman FA, et al. Choroidal and retinal thinning in chronic kidney disease independently associate with eGFR decline and are modifiable with treatment. Nat Commun. 2023;14(1):7720. doi:10.1038/s41467-023-43125-1
2. Wong CW, Wong TY, Cheng CY, Sabanayagam C. Kidney and eye diseases: common risk factors, etiological mechanisms, and pathways. Kidney Int. 2014; 85(6):1290-1302. doi:10.1038/ki.2013.491
3. Farrah TE, Dhillon B, Keane PA, Webb DJ, Dhaun N. The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons. Kidney Int. 2020;98(2):323-342. doi:10.1016/j.kint.2020.01.039
4. Booij JC, Baas DC, Beisekeeva J, Gorgels TG, Bergen AA. The dynamic nature of Bruch's membrane. Prog Retin Eye Res. 2010;29(1):1-18. doi:10.1016/j.preteyeres.2009.08.003
5. Boutaud A, Borza DB, Bondar O, et al. Type IV collagen of the glomerular basement membrane. J Biol Chem. 2000; 275(39):30716-30724. doi:10.1074/jbc.M004569200
6. Savige J, Sheth S, Leys A, Nicholson A, Mack HG, Colville D. Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol. 2015;10(4):703-709. doi:10.2215/CJN.10581014
Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
© 2024 MJH Life Sciences

All rights reserved.